

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION



INTERNATIONAL APPLICATION PUBLISHING

WO 9604025A1

(51) International Patent Classification 6 : <b>A61L 25/00</b>		A1	(11) International Publication Number: <b>WO 96/04025</b> (43) International Publication Date: 15 February 1996 (15.02.96)
(21) International Application Number: PCT/GB95/01804 (22) International Filing Date: 31 July 1995 (31.07.95)  (30) Priority Data: 9415739.3 30 July 1994 (30.07.94) GB		(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): SCIMAT LIMITED [GB/GB]; Dorcan 200, Murdock Road, Dorcan, Swindon SN3 5HY (GB).  (72) Inventor; and (75) Inventor/Applicant (for US only): HOBBS, Tracey, Susan [GB/GB]; 27 Cloverlands, Haydon Wick, Swindon SN2 3RW (GB).  (74) Agent: ORR, William, McLean; Urquhart-Dykes & Lord, Tower House, Merrion Way, Leeds, West Yorkshire LS2 8PA (GB).			
(54) Title: GEL WOUND DRESSING			
(57) Abstract <p>A gel wound dressing which comprises a water absorbent copolymer of a starch and a monounsaturated carboxylic acid or an ester or salt thereof, and water. Preferably, the particles of the copolymer are small, such that at least about 70 % of the particles have a particle size of not more than about 100 µm.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Lvvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

#### GEL WOUND DRESSING

This invention relates to a gel wound dressing material, and to techniques for preparing and using such a material.

It is desirable to control the condition of a wound to encourage the healing process by maintaining it sufficiently moist so as to absorb or to eliminate the formation of dry crusty tissue in the vicinity of the wound, while also absorbing materials exuded from the wound, including dead leucocytes, epidermal and dermal cells. At the same time, it is desirable to prevent access to the wound of agents, whether bacterial or fungal, which can lead to infection. Examples of wounds to which these factors are relevant are ulcers, traumatic and surgical wounds, and burns, and tissue donor sites.

Traditionally, wounds have been encouraged to heal by placing a gauze material over the wound. More recently, however, it has been proposed to apply a gel material over the wound. A suitable gel material is disclosed in US-4226232. It comprises a hydrolysed copolymer of starch and an acrylonitrile. The polymer is prepared in gel form by mixture with water, to an extent which gives the copolymer an appropriate viscosity which enables it to be manipulated as a gel, especially when applying it to a wound and while it is applied to the wound. Modified such materials are disclosed in US-4302369, in which the polymer is converted to its aluminium salt to increase its ability to absorb solutions with a high ionic strength.

Appropriate properties for a gel, for use as a wound dressing include a viscosity that makes the material capable of being manipulated before administration to a wound and then applied appropriately over the area of the wound, and an ability to absorb exudate from the wound. The need to be able to manipulate a gel material for a wound dressing conveniently has to be balanced with the ability of the gel to absorb additional

-2-

liquid; the mixture of the polymer with water to confer the gel viscosity on the polymer will result in a reduction of the ability of the polymer to absorb liquid.

The present invention provides a gel wound dressing in which the polymer component comprises a copolymer of a starch and a monounsaturated carboxylic acid or an ester or salt thereof.

Accordingly, in one aspect, the invention provides a gel wound dressing which comprises:

- (a) a water absorbent copolymer of a starch and a mono-unsaturated carboxylic acid or an ester or salt thereof; and
- (b) water.

The dressing material may further comprise a preservative or other additive.

The dressing of the invention has the advantage that it can be provided as a gel, and therefore be manipulated conveniently before application to a wound and while it is so applied, with an ability to absorb fluids which can be at least comparable with gel wound dressings based on other polymer systems. The dressing can also provide appropriate moisture levels to minimise the risk of a wound drying out during the healing process, which can itself give rise to complications in the healing process in terms of the formation of crusty tissue. The dressing material of the invention can be made with a viscosity which is at least about 100 cps, preferably at least about 125 cps, for example at least about 160 cps. The viscosity can be arranged to be not more than about 300 cps, more preferably not more than about 275 cps, for example not more than about 250 cps. The viscosity of the dressing material is measured on a Brookfield RVF viscometer with a helipath stand, using a T-bar D spindle at 4 rpm.

-3-

The viscosities referred to above can be attained according to the present invention while maintaining a high ability to absorb exuded materials from the wound as can be demonstrated by means of a saline absorption test. That test comprises dispersing 2 g of the dressing material in 20 ml of 0.9% aqueous NaCl solution. The dispersion is decanted into a 50 ml measuring cylinder. Once the dispersion has settled, the position of the phase separation is noted from which the fluid absorption capacity can be calculated. It has been found that the dressing material of the invention can be made with a viscosity within the limits mentioned above, with a saline absorption of at least about 200 ml of the solution per 100 g of the wound dressing, preferably at least about 250 ml.100 g<sup>-1</sup>, more preferably at least about 300 ml.100 g<sup>-1</sup>. The absorption characteristics of the dressing material have been found to be enhanced as a result of a sterilisation step in its preparation which involves exposing the material to heat and pressure. The viscosity that can be obtained in the material of the wound dressing material of the invention means that the material is capable of being manipulated conveniently over the area of the wound that is to be treated using the material. It also facilitates removal of the material from its packaging. In addition to facilitating manipulation, a relatively low viscosity can enable the tackiness of the material to be maintained relatively low, which reduces damage to the wound when the dressing is removed.

Control of the viscosity is one means of measurement which may be used to obtain a required ratio between copolymer and water in the gel mixture. However, other means may be adopted, to achieve desired water-absorption properties of the gel mixture, which effectively comprises required provision of a suitable "spreadable gel". This can range between "highly mobile" at one extreme to "very stiff" at the other extreme, and which can be obtained by variation of the proportion by weight of copolymer in the gel mixture between about 0.2% to about 6%. The particular weight proportion which may be selected can

-4-

depend on the particular means adopted to dispense the gel mixture, with e.g. a highly mobile gel being suitable for introduction into a deep wound by a syringe, and a stiffer gel being suitable for extrusion e.g. from a squeezable sachet so as to be readily spread over the wound area.

In one preferred arrangement, the gel mixture may be stored in a squeezable sachet, and therefore the required properties of the gel mixture will be such that it can be readily be squeezed from the sachet, and to be readily spread over the wound area.

The gel wound dressing of the invention has been found to be capable of providing suitable absorption characteristics, in particular towards solutions which are high in ionic strength, without any need to include aluminium ions. This can represent a significant advantage, in particular in situations in which the presence of aluminium ions can give rise to clinical complications.

Preferably, the gel wound dressing is formed from a mixture of particles of the copolymer and water, in which the distribution of particles is such that at least about 70% by weight, more preferably at least about 80%, especially at least about 90%, have a particle size of not more than about 100  $\mu\text{m}$ . Preferably, the gel wound dressing is formed from a mixture of particles of the copolymer and water, in which the distribution of particles is such that at least about 60% by weight, more preferably at least about 70%, especially at least about 85%, have a particle size of not more than about 75  $\mu\text{m}$ . Preferably, the distribution of particles is such that not more than about 10% by weight, more preferably not more than about 6%, have a particle size greater than about 100  $\mu\text{m}$ . The particle size distribution can be determined using sieves with known mesh sizes, as is known.

It has been found that the use of particles of the copolymer whose size satisfies some or all of these conditions gives rise

-5-

to materials with viscosities which make the copolymer suitable for use in the treatment of wounds, with the characteristics of a gel. The use of particles of the polymer with a size within these ranges has the advantage of making the material smoother without a granular texture. The smooth texture makes the material easier to spread appropriately over a wound that is to be treated. Also the gel usually will be clear i.e. transparent, so that the wound can be observed while the dressing is being applied.

Preferably, the gel wound dressing of the invention includes a component which reduces its tendency to dry out. This component may also act as a preservative. Examples of suitable materials include polyols, such as propane-1,2-diol and glycerol, or a mixture thereof. Preferably, the polyol component is present in the composition in an amount of at least about 100% by weight based on the weight of the copolymer, more preferably at least about 200%, especially at least about 300%, for example about 400%, and with advantage even up to 600%.

Preferably, the gel wound dressing of the invention includes at least one other active component. For example, the dressing might include an agent which inhibits or at least reduces the tendency for bacteria to colonise on the dressing. An example of a suitable such agent is a polyol such as propane-1,2-diol.

Examples of other active components that might be included in the dressing include anaesthetic agents, hormonal compounds and lubricants, enzyme-containing compositions, antibiotics (such as metronidazole), collagen materials, cytokines (such as platelet derived growth factor, insulin-dependent growth factor, and transforming factored placentile growth factor), and elastin (preferably with fibrin and fibrinogen).

The copolymer used in the dressing is produced by reaction of a starch with a monoethylenically unsaturated carboxylic acid,

-6-

or an ester or salt of such an acid. Examples of suitable components for the copolymer, together with the starch, include acrylic acid, methacrylic acid, lower carboxyl (C<sub>1</sub> to C<sub>4</sub>) esters thereof and salts such as with elements of Groups I and II or ammonia. It is preferred that substantially all of the carboxyl groups in the copolymer are present as acid groups, or as salt or ester derivatives of acid groups.

A particularly preferred copolymer comprises at least about 50%, preferably at least about 70%, more preferably at least about 85%, for example at least about 95%, of a salt of a starch grafted polyacrylate. Preferred salts include the sodium salt.

The copolymerisation reaction between the starch and the acrylate component can be initiated by means of irradiation, for example using an electron beam,  $\gamma$ -radiation such as from a Co<sup>60</sup> source, or ultraviolet radiation. The reaction can also be initiated by means of a chemical initiator such as benzoyl peroxide, hydrogen peroxide or a salt such as a ceric salt.

Examples of suitable copolymers for use in the gel wound dressing of the invention are disclosed in GB-1512325. Subject matter disclosed in that document is incorporated in the specification of this application by this reference. The document discloses a water absorbing resin which comprises a copolymer of starch and a water soluble monomer such as acrylic acid or a derivative thereof. The resin is crosslinked as a result of a reaction with a crosslinking agent such as polyesters of unsaturated mono- or polycarboxylic acids with polyols (for example an ester of di-methacrylic acid with ethylene glycol). The resin is said to be suitable for absorbing fluids such as blood and urine, for example in diapers, sanitary towels and disposable dustcloths for kitchens. The disclosed resin can be applied in the form of a powder, in an aqueous dispersion, or by immersion of a

-7-

substrate in a solution of the resin. The resin is said to be particularly suitable for use in diapers and sanitary towels.

The copolymer used in the dressing of the invention will generally be crosslinked, so as to confer appropriate gel-like properties and viscosity on the dressing material. The crosslinks will preferably be internal crosslinks. It has been found that the use of a polymer which is crosslinked in this way gives rise to a smoother dressing material, which has advantages in use for example in terms of its ability to be spread.

The starch used to form the copolymer may be a natural starch such as potato starch, rice starch, tapioca starch or corn starch, or a modified or processed starch such as  $\alpha$ -starch, dextrine and oxidised starch. Natural starches are particularly preferred.

The ratio by weight of the starch to the acid derivative component of the copolymer is preferably at least about 1, more preferably at least about 2, especially at least about 5, for example at least about 10. The ratio is preferably not more than about  $10^4$ , more preferably not more than about  $10^3$ , especially not more than about 100.

Suitable starch acrylate copolymers for use in the wound dressing of the invention are available from Hoechst Celanese under the trade mark SANWET COS-915.

Preferably, the water that is present in the wound dressing gel is not more than about 60% of the total water absorbency of the copolymer, more preferably not more than about 5%, for example not more than about 3%.

The water absorbency of the copolymer is determined by immersing in deionised water a known weight of the gel (1 to 2 g) made to the exemplified formulation, contained in a sealed

-8-

bag of a hydrophilic polypropylene based non-woven fabric available from Scimat Limited under the trade mark SCIMAT 700/13, and recording its weight change after 24 hours.

Prior to weighing, the surface of the bag is blotted to remove excess water and an empty bag is used as a control.

The total absorbency of the resin, measured in ml.g<sup>1</sup>, is calculated as follows:

$$\text{Absorbency} = \frac{(\text{Water in gel}) + (\text{Water uptake in } 24\text{h})}{\text{Resin in gel}}$$

However, the total water absorbency (T) can be difficult to measure in practice (due to variation between different batches of material), but tests carried out to date give the following desired parameters, wherein carrying out measurements for values from 900 to 1300 ml/g for pure water:

$$\text{In the formula: } R = \frac{Y}{xT} \times 100\%$$

in which R is the percentage proportion by weight of water present in the gel mixture relative to the total water absorbency of the copolymer in the gel mixture; T is the total water absorbency; X is the percentage by weight of copolymer in the copolymer/water gel mixture, and Y = amount of water added in the mixing stage.

For values of x = 0.2 and T = 900 and 1300 and Y = 99.8, the values of R were found to be 55.4 and 38.4 respectively.

For value of x = 6, and values of T = 900 and T = 1300 and Y = 94, the values of R were found to be 1.74 and 1.21 respectively.

-9-

The value of  $x = 0.2$  gives a gel mixture which is very runny, or "highly mobile" as indicated earlier, whereas the value  $x = 6.0$  gives a gel mixture which is very stiff. These two values of  $x$  determine the range within which a suitable spreadable gel can be derived, to suit particular requirements. Therefore, suitable variation of the weight proportions of copolymer and water in the gel mixture may be selected, by experiment, within the range, to provide spreadable gel mixtures suitable for different requirements.

In a preferred example, which contains 3.5 parts copolymer and 75.5 parts water, then when  $T = 900$ ,  $R = 2.4$ ; and when  $T = 1300$ ,  $R = 1.66$ , and  $Y = 75.5$ .

Accordingly, in a particularly preferred range of proportion by weight of copolymer to water in a gel mixture of a gel wound dressing according to the invention, the relative proportion of water that is present in a particular sample, compared with the total water absorbency of the copolymer in the sample, lies in a range having a minimum value of up to 1.0%. The upper limit to the preferred range will be determined by experiment, but may go up to as high a value as  $R = 60\%$ .

If desired, for certain circumstances it may be advantageous to introduce substantial amounts of preservative e.g. a polyol into the gel mixture, (which replaces the amount of water required in the formulation of the gel), and this can then result in a lower value of  $R$ . By way of example, in a gel mixture of 3% polymer, 69% polyol, and 28% water, the value of  $R$  is reduced to 0.7. The invention therefore includes the possibility of including weight proportions in the gel mixture of polymer, preservative, and water such that  $R$  can be less than 1.0%, and down to at least 0.7%.

The gel dressing will generally be applied to a wound in a layer of thickness at least about 2 mm, preferably at least about 4 mm, for example at least about 5 mm. A dressing

-10-

applied to certain wounds with this thickness can be left *in situ* for as much as seven days or more.

The dressing of the invention can be administered in a sachet from which it can be extruded through an opening, formed for example by means of a knife, by the application of pressure to the sachet.

The dressing can conveniently be administered in a syringe, from which it can be extruded in a controlled manner directly onto a wound so that it is appropriately located to ensure that the wetness of the wound is controlled.

The dressing can be administered in a porous container such as a pouch or sachet made of a material that is suitably porous to the fluids to be absorbed by the dressing when in place on the wound. Examples of materials that might be suitable for the sachet or pouch include paper based materials and organic materials such as polyamides and polyesters, especially in the form of a non-woven sheet.

The wound dressing of the invention can conveniently be applied directly to a wound. It is envisaged that, in most circumstances, the dressing will be changed after a period of, perhaps, hours or days, according to the condition of the wound, for example about 2 to 3 days (although shorter periods can be appropriate under certain conditions, for example when the amount of material exuding from the wound is high). When the dressing is to be changed, the gel-like characteristics of the dressing material facilitate its removal from the wound, and which may be assisted by irrigation, for example using a sterile saline solution.

It will generally be appropriate for a secondary dressing to be applied over the gel wound dressing, to retain it in place on a wound and to provide a degree of physical protection for the gel dressing. The nature of the secondary dressing will depend

-11-

on the characteristics of the wound. For example, if the wound has eschar (dry crusty tissue) associated with it, a moisture vapour permeable dressing will be appropriate. If the wound is malodorous, an activated carbon dressing can be appropriate.

An appropriate secondary dressing can preferably exclude bacteria from the wound, retain the dressing material in place on the wound, and permit exchange of moisture with the atmosphere. Preferably, the dressing is transparent so that the wound can be inspected. Suitable secondary dressings are sold under the trade marks OPSITE and TEGADERM.

The invention also provides a method of making a gel wound dressing material, which comprises mixing a water absorbent copolymer of a starch and a monounsaturated carboxylic acid or an ester or salt thereof with a quantity of water, the proportions of the copolymer and water being such that the resulting mixture has gel properties.

Preferably, the method includes the step of sterilising the gel wound dressing, for example by means of a heating step, optionally under pressure, or by irradiation if the materials of the dressing are not affected adversely by irradiation. Unexpectedly the saline absorbency capacity of the sterilised gel is greater than that before sterilisation.

The invention further provides a method of treating a wound which includes the step of applying a gel wound dressing of the type discussed above.

An example of a gel wound dressing will now be described. The dressing was made from a starch acrylate copolymer sold under the trade mark SANWET COS-915. It is supplied by Hoechst Celanese. Typically it has a particle size distribution as follows:

-12-

US SIEVE SIZE (mesh)	PARTICLE SIZE ( $\mu\text{m}$ )	SIZE DISTRIBUTION (wt %)	
		Sample 1	Sample 2
+20	>850	0.1	0.0
-20/+140	100-850	1.9	0.3
-140/+200	75-100	11.7	0.7
-200/+325	45-75	38.8	43.7
-325	<45	47.6	55.0

The following components were mixed mechanically for 3 minutes until dispersed evenly (amounts expressed in parts by weight):

Starch acrylate copolymer	3.5
Propane-1,2-diol	20.0
Glycerol	1.0

75.5 parts by weight of water were added to the resulting mixture and the resulting mixtures was stirred for a further 2 minutes until a homogeneous mixture was obtained.

The mixture was transferred to a shallow container and placed under a vacuum at room temperature to remove entrapped air.

Saline absorption was determined as follows. 2 g of gel was weighed into a beaker and 20 ml of 0.9% sodium chloride solution added. Once dispersed, the resulting dispersion was transferred to a 50 ml measuring cylinder. After settling, the volumes of the two layers was measured and the fluid absorbtion capacity calculated, as above.

Results for the formulation given in the example were as follows:

Absorbency before sterilisation	325 ml.100 g <sup>-1</sup> gel
Absorbency after sterilisation	400 ml.100 g <sup>-1</sup> gel

-13-

CLAIMS:

1. A gel wound dressing which comprises:
  - (a) a water absorbent copolymer of a starch and a mono-unsaturated carboxylic acid or an ester or salt thereof; and
  - (b) water.
2. A wound dressing as claimed in claim 1, which includes a component which reduces the tendency of the dressing to dry out when exposed to atmosphere.
3. A wound dressing as claimed in claim 2, in which the said component comprises a polyol.
4. A wound dressing as claimed in claim 2 or claim 3, in which the said component comprises propane-1,2-diol.
5. A wound dressing as claimed in any one of claims 2 to 4, in which the said component is present in an amount of at least 100% based on the weight of the copolymer.
6. A wound dressing as claimed in any one of claims 1 to 5, which includes agent which inhibits or at least reduces the tendency for bacteria to colonise on the dressing.
7. A wound dressing as claimed in any one of claims 1 to 6, which is formed from a mixture of particles of the copolymer and water, in which the distribution of the particles is such that at least about 70% by weight, more preferably at least about 80%, especially at least about 90%, have a particle size of not more than about 100  $\mu\text{m}$ .
8. A wound dressing as claimed in any one of claims 1 to 7, in which substantially all of the carboxyl groups in the

-14-

copolymer are present as acid groups, or as salt or ester derivatives of acid groups.

9. A wound dressing as claimed in any one of claims 1 to 8, in which the wound dressing comprises a spreadable gel mixture.

10. A wound dressing as claimed in any one of claims 1 to 9, in which the proportion by weight of copolymer (X %) lies in the range from 0.2 to 6%.

11. A wound dressing as claimed in any one of claims 1 to 10, in which: in the formula

$$R = \frac{Y}{xT} \times 100\%,$$

where R is the percentage proportion by weight of water present in the mixture relative to the total water absorbency of the copolymer, where T is the total water absorbency, x is the percentage by weight of copolymer, and Y= amount of water added in the mixing stage:

R has a minimum value of up to 1.0%.

12. A wound dressing as claimed in Claim 11, in which the ratio R lies in a range up to 60%.

13. A wound dressing as claimed in Claim 2, in which the relative weight proportions of co-polymer, preservative component and water in the gel mixture are such that the percentage proportion by weight of water present in the mixture relative to the total water absorbency of the co-polymer (R) has a minimum value of up to 0.7%.

14. A wound dressing as claimed in any of claims 1 to 13, which is contained in a syringe.

-15-

15. A wound dressing as claimed in any one of claims 1 to 13, which is contained in a sachet from which the dressing can be extruded by application of pressure.

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 95/01804

**A. CLASSIFICATION OF SUBJECT MATTER**  
**IPC 6 A61L25/00**

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

**IPC 6 A61L**

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,91 15368 (PROCTER & GAMBLE) 17 October 1991 see claims ----	1-8
X	EP,A,0 509 708 (DOW CHEMICAL CO) 21 October 1992 see claims; examples ----	1-5
X	PATENT ABSTRACTS OF JAPAN vol. 015 no. 357 (C-0866) ,10 September 1991 & JP,A,03 141229 (SANYO CHEM IND LTD) 17 June 1991, see abstract ----	1,6
X	EP,A,0 309 187 (JOHNSON & JOHNSON) 29 March 1989 see claims ----	1
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*A\* document member of the same patent family

Date of the actual completion of the international search

7 December 1995,

Date of mailing of the international search report

19.12.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+ 31-70) 340-3016

Authorized officer

ESPINOSA, M

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 95/01804

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 157 960 (PERSONAL PRODUCTS CO) 16 October 1985 see page 2, line 25 - line 27 see page 4, line 23 - line 30; examples ---	1
A	US,A,4 226 232 (SPENCE WAYMAN R) 7 October 1980 cited in the application see claims -----	1

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 95/01804

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9115368	17-10-91	US-A-	5384179	24-01-95
		US-A-	5300565	05-04-94
		AU-B-	660924	13-07-95
		AU-B-	7674991	30-10-91
		CA-A-	2079452	03-10-91
		CN-A-	1056111	13-11-91
		EG-A-	19391	30-08-95
		EP-A-	0525049	03-02-93
		US-A-	5330822	19-07-94
		US-A-	5397626	14-03-95
EP-A-0509708	21-10-92	AU-B-	1487992	22-10-92
		JP-A-	5156034	22-06-93
EP-A-0309187	29-03-89	US-A-	4826880	02-05-89
		AU-B-	2223788	20-04-89
		CA-A-	1318655	01-06-93
		GR-B-	1000150	27-09-91
		JP-A-	1230671	14-09-89
EP-A-0157960	16-10-85	AU-B-	567728	03-12-87
		AU-B-	2615484	03-10-85
		GB-A,B	2156370	09-10-85
		JP-B-	6073630	21-09-94
		JP-A-	60212162	24-10-85
		PT-A-	78475	09-05-85
US-A-4226232	07-10-80	DE-A-	3011664	23-10-80
		GB-A-	2048292	10-12-80
		JP-A-	56005663	21-01-81